MedCap AB (SE:MCAP)
:MCAP
MCAP Stock Chart & Stats
kr533.00
-kr4.00(-1.07%)
At close: 4:00 PM EST
kr533.00
-kr4.00(-1.07%)
Day’s Range― - ―
52-Week Rangekr329.00 - kr677.00
Previous CloseN/A
Volume7.13K
Average Volume (3M)21.82K
Market Cap
kr7.03B
Enterprise Valuekr7.34B
Total Cash (Recent Filing)kr370.40M
Total Debt (Recent Filing)kr707.00M
Price to Earnings (P/E)37.4
Beta0.61
Next Earnings
Apr 29, 2026EPS Estimate
4.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.83
Shares Outstanding15,077,583
10 Day Avg. Volume14,106
30 Day Avg. Volume21,821
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.59
Revenue Forecast (FY)kr2.23B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthMedCap’s top line has more than doubled over the 2020–2025 period, indicating durable expansion across its operating subsidiaries. Sustained revenue growth supports operating leverage, provides internal funding for bolt-on M&A and reinvestment, and strengthens long-term cash generation capacity.
Consistent Operating ProfitabilityThe group’s mid‑teens EBIT margins and steady operating profitability across portfolio companies show structural margin strength. Persistent margins improve resilience to cyclical shocks, enable reinvestment in growth initiatives, and support sustained earnings generation over the medium term.
Positive Free Cash FlowConsistent and growing free cash flow provides a durable source of liquidity for debt servicing, internal financing of acquisitions, and potential upstreaming to the parent. A positive FCF profile reduces reliance on external capital and underpins long‑term financial flexibility.
Bears Say
Rising LeverageA meaningful increase in leverage in 2025 reduces balance‑sheet flexibility and raises interest and refinancing risk. Higher indebtedness can constrain the firm’s ability to pursue opportunistic M&A, makes cash flows more sensitive to rate moves, and limits shock absorption capacity.
Uneven Cash ConversionRepeated instances where operating cash flow lags reported earnings point to working‑capital swings or timing effects that weaken earnings quality. Persistent uneven cash conversion can strain near‑term liquidity, complicate dividend or upstreaming plans, and increase vulnerability in downturns.
Gross-Margin VolatilityA pronounced gross‑margin drop in 2025 suggests adverse mix, pricing pressure, or cost spikes. If margin volatility persists it could compress durable profitability, reduce cash flow stability, and necessitate margin restoration actions that limit reinvestment and strategic flexibility.
MedCap AB News
MCAP FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was kr329.00 and its highest was kr677.00 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is kr7.03B.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 34 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported kr4.835 earnings per share for the quarter, beating the consensus estimate of kr4.755 by kr0.08.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 4.73.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of kr4.835 in its last earnings report, beating expectations of kr4.755. Following the earnings report the stock price went up 9.567%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in SE:MCAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---